Javascript must be enabled to continue!
Positive Feedback of Vasopressin on its Own Release in the Central Nervous System: in vitro Studies
View through CrossRef
AbstractIn this paper evidence is shown that synthetic arginine vasopressin (AVP) can evoke marked in vitro release of endogenous immunoreactive AVP (I‐AVP) from male rat septal and hypothalamic tissue superfused in vitro. The stimulatory action was dosedependent with a maximal amplification factor of 2.3 when using 14 pg of synthetic AVP as the stimulus. It was highly specific since only AVP was effective and not three closely related substances such as lysine vasopressin, oxytocin and a 4–9 C fragment of AVP. This reproducible effect of AVP required, however, effective concentrations of bacitracin (10−4 to 10−5 M) in the superfusion medium to inhibit aminopeptidase(s) capable of inactivating AVP. Lastly, the stimulatory action of AVP on its own release was not blocked by a V1‐receptor antagonist of AVP but was blocked by a V2‐antagonist. It is proposed that this novel and robust positive feedback of AVP on its own release may be involved in the mechanism of memory consolidation of certain behavioral tasks known to be affected by AVP.
Title: Positive Feedback of Vasopressin on its Own Release in the Central Nervous System: in vitro Studies
Description:
AbstractIn this paper evidence is shown that synthetic arginine vasopressin (AVP) can evoke marked in vitro release of endogenous immunoreactive AVP (I‐AVP) from male rat septal and hypothalamic tissue superfused in vitro.
The stimulatory action was dosedependent with a maximal amplification factor of 2.
3 when using 14 pg of synthetic AVP as the stimulus.
It was highly specific since only AVP was effective and not three closely related substances such as lysine vasopressin, oxytocin and a 4–9 C fragment of AVP.
This reproducible effect of AVP required, however, effective concentrations of bacitracin (10−4 to 10−5 M) in the superfusion medium to inhibit aminopeptidase(s) capable of inactivating AVP.
Lastly, the stimulatory action of AVP on its own release was not blocked by a V1‐receptor antagonist of AVP but was blocked by a V2‐antagonist.
It is proposed that this novel and robust positive feedback of AVP on its own release may be involved in the mechanism of memory consolidation of certain behavioral tasks known to be affected by AVP.
Related Results
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women
Objective
To test binding affinities for, and inhibitory effects on, myometrium of some oxytocin and vasopressin antagonists with respect to their therapeutic potential.Desig...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Receptor‐mediated uterine effects of vasopressin and oxytocin in nonpregnant women
Receptor‐mediated uterine effects of vasopressin and oxytocin in nonpregnant women
ABSTRACTObjective
To study in nonpregnant women myometrial actions of vasopressin and oxytocin and the involvement in these effects of specific uterine receptors.Subjects
...
Vasopressin‐induced intracellular Ca2+ increase in isolated rat supraoptic cells.
Vasopressin‐induced intracellular Ca2+ increase in isolated rat supraoptic cells.
1. The intracellular Ca2+ concentration ([Ca2+]1) was monitored in single magnocellular neurones freshly isolated from rat supraoptic nucleus. Application of 100 nM vasopressin inc...
Inhibitory effects of SR 49059 on oxytocin‐and vasopressin‐induced uterine contractions in non‐pregnant women
Inhibitory effects of SR 49059 on oxytocin‐and vasopressin‐induced uterine contractions in non‐pregnant women
Background. Compounds that block uterine oxytocin and vasopressin V1a receptors have a therapeutic potential in preterm labor and primary dysmenorrhoea. The orally active vasopres...
Polycystic Kidney Disease and the Vasopressin Pathway
Polycystic Kidney Disease and the Vasopressin Pathway
Vasopressin, also known as arginine vasopressin or antidiuretic hormone, plays a pivotal role in maintaining body homeostasis. Increased vasopressin concentrations, measured by its...
Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin‐induced uterine contractions
Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin‐induced uterine contractions
Objective
To test the effect of SR 49059, an orally active, nonpeptide, selective and specific antagonist of the vasopressin V1a receptors in humans.Design
A placebo‐co...
Vasopressin Loading for Refractory Septic Shock: A Preliminary Analysis of a Case Series
Vasopressin Loading for Refractory Septic Shock: A Preliminary Analysis of a Case Series
Background: Vasopressin is one of the strong vasopressor agents associated with ischemic events. Responses to the administration of vasopressin differ among patients with septic sh...

